title: Health status of childhood leukemia survivors who received hematopoietic cell transplantation after BU or TBI: an LEA study.
abstract: The purpose of this multicenter study was to compare the long-term impact of a preparative regimen with either BUBU or TBI on health status and quality of life (QoL) in childhood acute leukemia survivors treated with hematopoietic SCT (HSCT). Two-hundred and forty patients were included. Sixty-six had received BU, while 174 had received TBI. Median follow-up from HSCT was 10.1 years. Multivariate analyses were performed to assess the occurrence of late effects according to treatment. QoL was assessed in 130 adults using SF-36 questionnaires. Patients developed fewer late complications after BU (2.35 vs 3.01, P=0.03) while the risk to present with at least one complication was equivalent in both groups (87.9% after BU and 93.1% after TBI, P=0.66). Detailed multivariate analyses revealed a lower risk of height growth failure (OR=0.2), cataract (OR=0.1) and iron overload (OR=0.2) after BU, and an increased risk of overweight (OR=3.9) and alopecia (OR=11.2). SF-36 mental and physical composite scores were similar in both treatment groups and proved significantly lower than French norms. Late effects induced by BU might differ from those experienced after TBI. Although less frequent, they are still of considerable importance and may affect patients' QoL.
authors.affiliation: Department of Pediatric Hematology-Oncology, La Timone Children's Hospital, Marseille, France.
authors.forename: F
authors.initials: F
authors.lastname: Bernard
authors.affiliation: Department of Public Health -EA 3279 Research Unit, University Hospital of Marseille, Aix-Marseille University, Marseille, France.
authors.forename: P
authors.initials: P
authors.lastname: Auquier
authors.affiliation: Department of Pediatric Hematology-Oncology, La Timone Children's Hospital, Marseille, France.
authors.forename: I
authors.initials: I
authors.lastname: Herrmann
authors.affiliation: Department of Pediatric Hematology-Oncology, Brabois Children's Hospital, Vandoeuvre-Les-Nancy, France.
authors.forename: A
authors.initials: A
authors.lastname: Contet
authors.affiliation: Department of Pediatric Hematology-Oncology, L'Archet II Hospital, Nice, France.
authors.forename: M
authors.initials: M
authors.lastname: Poiree
authors.affiliation: Department of Pediatric Hematology-Oncology, CIC Inserm 501, University Hospital of Clermont Ferrand, Clermont-Ferrand, France.
authors.forename: F
authors.initials: F
authors.lastname: Demeocq
authors.affiliation: Department of Pediatric Hematology-Oncology, University Hospital of Grenoble, Grenoble, France.
authors.forename: D
authors.initials: D
authors.lastname: Plantaz
authors.affiliation: Department of Pediatric Hematology-Oncology, La Timone Children's Hospital, Marseille, France.
authors.forename: C
authors.initials: C
authors.lastname: Galambrun
authors.affiliation: Department of Pediatric Hematology-Oncology, La Timone Children's Hospital, Marseille, France.
authors.forename: V
authors.initials: V
authors.lastname: Barlogis
authors.affiliation: Department of Public Health -EA 3279 Research Unit, University Hospital of Marseille, Aix-Marseille University, Marseille, France.
authors.forename: J
authors.initials: J
authors.lastname: Berbis
authors.affiliation: Department of Public Health -EA 3279 Research Unit, University Hospital of Marseille, Aix-Marseille University, Marseille, France.
authors.forename: F
authors.initials: F
authors.lastname: Garnier
authors.affiliation: Department of Pediatric Hematology-Oncology, Arnaud de Villeneuve Hospital, Montpellier, France.
authors.forename: N
authors.initials: N
authors.lastname: Sirvent
authors.affiliation: Department of Pediatric Hematology-Oncology, CIC Inserm 501, University Hospital of Clermont Ferrand, Clermont-Ferrand, France.
authors.forename: J
authors.initials: J
authors.lastname: Kanold
authors.affiliation: Department of Pediatric Hematology-Oncology, Brabois Children's Hospital, Vandoeuvre-Les-Nancy, France.
authors.forename: P
authors.initials: P
authors.lastname: Chastagner
authors.affiliation: Department of Pediatric Hematology-Oncology, La Timone Children's Hospital, Marseille, France.
authors.forename: H
authors.initials: H
authors.lastname: Chambost
authors.affiliation: 1] Department of Pediatric Hematology-Oncology, La Timone Children's Hospital, Marseille, France [2] Department of Public Health -EA 3279 Research Unit, University Hospital of Marseille, Aix-Marseille University, Marseille, France.
authors.forename: G
authors.initials: G
authors.lastname: Michel
mesh_terms: D000293:Adolescent; D002066:Busulfan / Q000008:administration & dosage / Q000009:adverse effects*; D002386:Cataract / Q000139:chemically induced; D002648:Child; D002675:Child, Preschool; D005260:Female; D005500:Follow-Up Studies; D006130:Growth Disorders / Q000139:chemically induced; D006304:Health Status; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000009:adverse effects; D007223:Infant; D019190:Iron Overload / Q000139:chemically induced; D015470:Leukemia, Myeloid, Acute / Q000628:therapy*; D008297:Male; D050177:Overweight / Q000139:chemically induced; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000628:therapy*; D011788:Quality of Life; D017741:Survivors; D013995:Time; D014916:Whole-Body Irradiation
chemical_list: D007166:Immunosuppressive Agents; D002066:Busulfan